Halozyme Therapeutics | HALO - Cost Of Sales

Stock Price
69.53
Daily Change
0.31 0.45%
Monthly
-4.53%
Yearly
17.55%
Q1 Forecast
68.78

Halozyme Therapeutics reported $102.15M in Cost of Sales for its fiscal quarter ending in December of 2025.





Cost Of Sales Change Date
Acadia Pharmaceuticals USD 26.22M 4.58M Dec/2025
Agios Pharmaceuticals USD 1.88M 199K Dec/2025
Alnylam Pharmaceuticals USD 267.72M 67.57M Dec/2025
Amarin USD 16.89M 18.51M Mar/2025
Amgen USD 1.79B 128M Dec/2025
Baxter International USD 2.4B 512M Dec/2025
Cara Therapeutics USD 0 0 Mar/2025
Cytokinetics USD 99.23M 13.32M Sep/2025
Eli Lilly USD 3.37B 363.7M Dec/2025
Esperion Therapeutics USD 51.63M 22.2M Sep/2024
Halozyme Therapeutics USD 102.15M 29.14M Dec/2025
Intrexon USD 1.01M 344K Jun/2024
Ionis Pharmaceuticals USD 8M 5.66M Dec/2025
MannKind USD 33.65M 13.44M Dec/2025
Minerva Neurosciences 386K 31K Jun/2024
Nektar Therapeutics USD 4.43M 5.3M Sep/2024
Pfizer USD 6.29B 2.12B Dec/2025
Rigel Pharmaceuticals USD 8.03M 5.22M Sep/2024
United Therapeutics USD 474.7M 373.8M Dec/2025
Vanda Pharmaceuticals USD 198.77M 151.12M Dec/2024